Goldman Sachs Group Inc Iovance Biotherapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$613 Billion
Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 4,110,056 shares of IOVA stock, worth $23.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,110,056

Previous 4,390,032 6.38%

Holding current value

$23.8 Million

Previous $41.2 Million 26.22%

% of portfolio

0.0%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$7.17 - $12.28 $2.01 Million - $3.44 Million	-279,976 Reduced 6.38%	4,110,056 $30.4 Million
Q3 2024 Nov 14, 2024	BUY	$7.28 - $11.9 $12.9 Million - $21 Million	1,768,248 Added 67.44%	4,390,032 $41.2 Million
Q2 2024 Aug 13, 2024	SELL	$7.78 - $14.19 $9.03 Million - $16.5 Million	-1,160,779 Reduced 30.69%	2,621,784 $21 Million
Q1 2024 May 15, 2024	BUY	$7.59 - $17.47 $766,612 - $1.76 Million	101,003 Added 2.74%	3,782,563 $56.1 Million
Q4 2023 Feb 13, 2024	SELL	$3.3 - $8.89 $270,857 - $729,673	-82,078 Reduced 2.18%	3,681,560 $29.9 Million
Q3 2023 May 14, 2024	BUY	$4.44 - $8.79 $364,426 - $721,465	82,078 Added 2.23%	3,763,638 $17.1 Million
Q3 2023 Nov 14, 2023	BUY	$4.44 - $8.79 $1.01 Million - $2.01 Million	228,371 Added 6.46%	3,763,638 $17.1 Million
Q2 2023 May 14, 2024	SELL	$5.36 - $9.06 $2.13 Million - $3.6 Million	-397,717 Reduced 10.11%	3,535,267 $24.9 Million
Q2 2023 Aug 14, 2023	SELL	$5.36 - $9.06 $2.13 Million - $3.6 Million	-397,717 Reduced 10.11%	3,535,267 $24.9 Million
Q1 2023 May 14, 2024	BUY	$5.53 - $8.22 $1.6 Million - $2.38 Million	289,919 Added 7.96%	3,932,984 $24 Million
Q1 2023 May 11, 2023	BUY	$5.53 - $8.22 $1.6 Million - $2.38 Million	289,919 Added 7.96%	3,932,984 $24 Million
Q4 2022 May 14, 2024	BUY	$5.62 - $10.0 $3.64 Million - $6.48 Million	648,086 Added 21.64%	3,643,065 $23.3 Million
Q4 2022 Feb 13, 2023	BUY	$5.62 - $10.0 $3.64 Million - $6.48 Million	648,086 Added 21.64%	3,643,065 $23.3 Million
Q3 2022 May 14, 2024	BUY	$9.53 - $13.11 $9.94 Million - $13.7 Million	1,042,633 Added 53.4%	2,994,979 $28.7 Million
Q3 2022 Nov 10, 2022	BUY	$9.53 - $13.11 $9.94 Million - $13.7 Million	1,042,633 Added 53.4%	2,994,979 $28.7 Million
Q2 2022 May 14, 2024	SELL	$6.38 - $18.33 $11 Million - $31.7 Million	-1,729,214 Reduced 46.97%	1,952,346 $21.6 Million
Q2 2022 Aug 15, 2022	BUY	$6.38 - $18.33 $8.79 Million - $25.3 Million	1,377,975 Added 239.91%	1,952,346 $21.6 Million
Q1 2022 May 16, 2022	SELL	$12.38 - $19.1 $10.8 Million - $16.7 Million	-875,433 Reduced 60.38%	574,371 $9.56 Million
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $3.22 Million - $5.38 Million	194,704 Added 15.51%	1,449,804 $27.7 Million
Q3 2021 Nov 10, 2021	BUY	$20.35 - $26.63 $25.5 Million - $33.4 Million	1,255,100 New	1,255,100 $31 Million

Others Institutions Holding IOVA

# of Institutions

340

Shares Held

247M

Call Options Held

2.51M

Put Options Held

3.5M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $912M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Iovance Biotherapeutics, Inc. Transaction History